GlassScriptPhysician profile
Sara Forman
NPI 1902271331
$5,033.73
in general payments reported to CMS, 2019-2025
26 companies · $2,404 in 2025
The $2,404 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $44.45 · 2023: $530 · 2024: $1,879 · 2025: $2,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,696 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,695.89 |
| Education | $116.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,136.94 | 2021-2025 | |
| Janssen Biotech, INC. | $563.04 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $497.94 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $394.17 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.30 | 2021-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $310.26 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $238.51 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $225.05 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $185.89 | 2023-2025 | Ibsrela |
| Vivus LLC | $179.04 | 2023-2025 | Pancreaze |
| Lilly USA, LLC | $163.33 | 2023-2025 | Omvoh |
| Pfizer INC. | $156.57 | 2024-2025 | |
| Celltrion USA INC. | $139.71 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $126.34 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $76.22 | 2024-2025 | Zenpep |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $55.43 | 2023-2025 | Linzess |
| Lucid Diagnostics INC. | $45.21 | 2025 | |
| Novo Nordisk INC | $30.08 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $23.54 | 2025 | Rebyota |
| Braintree Laboratories, INC. | $22.04 | 2024 | Sutab, Suflave |
| Sandoz INC. | $21.98 | 2024 | Hyrimoz |
| Axonics, INC. | $19.30 | 2024 | Axonics |
| Redhill Biopharma INC. | $18.87 | 2024 | Talicia, Aemcolo |
| Olympus America INC. | $18.26 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.80 | 2025 | Iqirvo |
| Shield Therapeutics INC | $13.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.